Table 2.
Treatment effect, 3, between pre-treatment and 12 weeks in untreated control and Capadenoson (CAP)-treated dogs.
| Control | Capadenoson | P-value | |
|---|---|---|---|
| ΔHR (beats/min) | −1.67 ± 2.7 | −3.67 ± 5.3 | 0.74 |
| ΔmAoP (mmHg) | 6.3 ± 0.8 | −1 ± 5.4 | 0.2 |
| ΔCO (L/min) | 0.1 ± 0.1 | 0.61 ± 0.2 | 0.02 |
| ΔLV ESP (mm Hg) | 5 ± 2 | 1 ± 7 | 0.57 |
| ΔTau (msec) | 9 ± 10 | −12 ± 7 | 0.11 |
| ΔLV +dP/dt (mmHg/sec) | 4 ± 60 | 163 ± 131 | 0.30 |
| ΔSVR (dynes/sec/cm−5) | 102 ± 146 | −948 ± 195 | 0.002 |
| ΔEi/Ai | 0.4 ± 0.4 | 0.7 ± 0.4 | 0.58 |
| ΔDT (msec) | −2.2 ± 2.2 | 3.0 ± 3.9 | 0.26 |
| ΔLV EDWS (gm/cm^2) | 13.2 ± 7.8 | −8.8 ± 11.4 | 0.14 |
| ΔSlope of ESPVR (mmHg/ml) | −1.2 ± 0.9 (n=3) | −0.23 ± 0.1 (n=3) | 0.34 |
| ECG from Holter | |||
| Max HR (beats/min) | −10 ± 11 | −0.8 ± 10 | 0.48 |
| Avg HR (beats/min) | −8 ± 2 | −8 ± 4 | 0.97 |
| Min HR (beats/min) | −5 ± 3 | −7 ± 3 | 0.67 |
Data are shown as Mean ± SEM. Max = maximum; Avg = average; Min = minimum; ECG = electrocardiogram; Other abbreviations as in Table 1. P-value = probability Control vs. Capadenoson.